Final Report of the Lyme Disease Review Panel of the Infectious Diseases Society of America

In April 2008, the Infectious Diseases Society of America (IDSA) entered into an agreement with Connecticut Attorney General Richard Blumenthal to voluntarily undertake a special review of its 2006 Lyme disease guidelines. This agreement ended the Attorney General's investigation into the proce...

Full description

Saved in:
Bibliographic Details
Published in:Clinical infectious diseases 2010-07, Vol.51 (1), p.1-5
Main Authors: Lantos, Paul M., Charini, William A., Medoff, Gerald, Moro, Manuel H., Mushatt, David M., Parsonnet, Jeffrey, Sanders, John W., Baker, Carol J.
Format: Article
Language:English
Subjects:
Anti-Bacterial Agents - administration & dosage
Anti-Bacterial Agents - adverse effects
Antibiotics
Antitrust Laws
Attorneys general
Babesiosis
Bacterial diseases
Biological and medical sciences
Borrelia
Borrelia infections
Conflict of Interest
Conflicts of interest
Connecticut
Drug Administration Schedule
Guidelines
Health Policy
Human bacterial diseases
Humans
IDSA PUBLIC POLICY
Infectious diseases
Lyme disease
Lyme Disease - therapy
Medical sciences
Nervous system diseases
Neurology
Ombudsmen
Practice Guidelines as Topic
Public policy
Recommendations
Societies, Medical - legislation & jurisprudence
Symptoms
Tropical bacterial diseases
United States
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:In April 2008, the Infectious Diseases Society of America (IDSA) entered into an agreement with Connecticut Attorney General Richard Blumenthal to voluntarily undertake a special review of its 2006 Lyme disease guidelines. This agreement ended the Attorney General's investigation into the process by which the guidelines were developed. The IDSA agreed to convene an independent panel to conduct a one-time review of the guidelines. The Review Panel members, vetted by an ombudsman for potential conflicts of interest, reviewed the entirety of the 2006 guidelines, with particular attention to the recommendations devoted to post—Lyme disease syndromes. After multiple meetings, a public hearing, and extensive review of research and other information, the Review Panel concluded that the recommendations contained in the 2006 guidelines were medically and scientifically justified on the basis of all of the available evidence and that no changes to the guidelines were necessary.
ISSN:1058-4838
1537-6591
DOI:10.1086/654809